tiprankstipranks
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
US Market
RNAC
Cartesian Therapeutics
RESEARCH TOOLSreports

Cartesian Therapeutics (RNAC) Stock News & Sentiment

1,150 Followers
Buy Rating on Cartesian Therapeutics (RNAC) Driven by Strong Strategic Vision, Clinical Roadmap, and Attractive Risk‑Reward Profile
Premium
Ratings
Buy Rating on Cartesian Therapeutics (RNAC) Driven by Strong Strategic Vision, Clinical Roadmap, and Attractive Risk‑Reward Profile
1d ago
RNAC
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
Premium
Company Announcements
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
16d ago
8K
RNAC
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
Premium
Company Announcements
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
1M ago
RNAC
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
Premium
Ratings
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
1M ago
RNAC
RNAC Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
RNAC Upcoming Earnings Report: What to Expect?
1M ago
RNAC
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
Premium
Company Announcements
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
3M ago
8K
RNAC
Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
Premium
Ratings
Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
4M ago
RNAC
More RNAC News >

RNAC News on the Web

Buy Rating on Cartesian Therapeutics (RNAC) Driven by Strong Strategic Vision, Clinical Roadmap, and Attractive Risk‑Reward Profile
TipRanks News
Bullish
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
TipRanks News
Bearish
Squarepoint Ops LLC Acquires Significant Stake in Cartesian Therapeutics Inc
GuruFocus News
Bullish
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
TipRanks News
Bullish
Wedbush Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)
TipRanks News
Bearish
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC)
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Cartesian Therapeutics (RNAC)
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
RNAC
Sector Average
Media Buzz
This Week1 articles
Weekly Average1 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is RNAC’s Media Buzz Sentiment?
1 articles about RNAC were published this week. In an average week, 1 articles are published.
    What is RNAC’s weekly average amount of articles?
    In an average week, 1 articles about RNAC are published.
      What is RNAC’s News Sentiment?
      100% of articles about RNAC were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        TXTMProText Mobility
        ALLOAllogene Therapeutics
        STAAStaar Surgical
        REPLReplimune Group
        IVVDInvivyd
        Showing the stocks with the most bullish news sentiment over the past week